about
Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson diseaseNovel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson diseaseNew melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.Trophic effects of insulin-like growth factor-I (IGF-I) in the inner ear.PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosisGlycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: role of C/EBPβ.Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders.Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition.CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor.Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice.CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's diseaseAnticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats.Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo.NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders.Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-β-carboline (Pinoline) and Melatonin-Pinoline Hybrids.Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivoNew flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic propertiesNovel Approaches for the Treatment of Alzheimer's and Parkinson's DiseasePhosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease
P50
Q28476019-5948FB00-4BE0-4534-8DA3-C2ED630DD47DQ28742424-29ADC65A-7A8D-4806-AD56-C4B2064EC8F8Q30961259-0BF6C741-5D82-4D2B-9A00-585F24A02830Q33902992-3B04A529-6DA0-46C7-B360-01814C820DECQ34591684-76742FEA-4C40-4D7A-AEED-1540E4DF20B3Q35150027-61598DDC-E4BD-4400-9394-8ADAB00A1EE3Q35665339-6647B2E5-88DE-4B82-8EC4-A392027D7761Q35908802-DE1E4BE0-BAB1-4781-9CEF-6BCBC57FD128Q36016406-65234D18-C8E8-44B5-8D3E-BAA026F2F53AQ36415259-2D10E2AF-63DE-40B8-966F-1F020B587C28Q37356880-3C12ED83-2B29-4CAE-A545-932693A9145CQ37657490-1F0BCFBE-1CE2-42E0-8469-871BA3E52D3DQ38686069-D01E3967-F963-49F2-B53A-623B65D80D3FQ38766306-31BCF05D-38D4-4119-8334-10D0C21C710BQ38842928-3593C4C1-8F1C-471C-912F-BECECC278B18Q38916940-0004E30C-E395-4988-98C8-FB1B60B30F1DQ41745623-CF1E5F33-0972-4CE8-AEF6-DB20065FEA24Q42670542-05B84720-F663-42D5-9E4F-BFC05FC649D5Q45946742-EB0D83D8-A599-47A2-B429-B6FA05513C96Q47807546-79B74097-8F58-4A9E-A6F2-06C63A6B3850Q48105573-B4743BDC-33FB-4B22-9AFF-0ECDFA6CAE4BQ48157997-088FC19B-6AB9-4AF4-85C9-AB20079B5300Q48259483-DFB66726-D5C8-4007-9F95-E7A3E3F1D0CBQ48327551-53B56106-53A5-4E8C-8686-03B66AE012B6Q48631317-96EABCD1-F48F-4605-83CE-57849EBF9417Q48704925-1B1AE48C-FFFF-43F3-921A-01EB5BAADAA3Q57714157-FBCE62B4-8673-4952-BD46-D1EB5D120326Q64121987-000E0EAD-760D-4BCB-93FF-2E74F5EAD50BQ64272978-2D045E16-B6D4-42AE-92B9-D44E9A5F50B6Q93040126-4FB4A561-1DDF-4000-9A32-220003C55AC4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jose A Morales-Garcia
@ast
Jose A Morales-Garcia
@en
Jose A Morales-Garcia
@es
Jose A Morales-Garcia
@nl
Jose A Morales-Garcia
@sl
type
label
Jose A Morales-Garcia
@ast
Jose A Morales-Garcia
@en
Jose A Morales-Garcia
@es
Jose A Morales-Garcia
@nl
Jose A Morales-Garcia
@sl
prefLabel
Jose A Morales-Garcia
@ast
Jose A Morales-Garcia
@en
Jose A Morales-Garcia
@es
Jose A Morales-Garcia
@nl
Jose A Morales-Garcia
@sl
P1053
L-4552-2014
P106
P1153
16549925000
P21
P2798
P31
P3829
P4012
P496
0000-0001-9008-0056